Open AccessIschemia‐Modified albumin levels in patients with end‐stage renal disease patients on hemodialysis: does albumin analysis method affect albumin‐adjusted Ischemia‐Modified albumin levels?
Author(s) -
Kıyıcı Aysel,
Mehmetoğlu İdris,
Karaoğlan Hatice,
Atalay Hüseyin,
Solak Yalçın,
Türk Süleyman
Publication year - 2010
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.20399
Subject(s) - albumin , ischemia modified albumin , medicine , hemodialysis , ischemia , end stage renal disease , serum albumin , myocardial ischemia
Ischemia‐Modified albumin (IMA) has been used as an early marker in the evaluation of the patients with acute coronary syndrome. We aimed to evaluate IMA in end‐stage renal disease (ESRD) patients on hemodialysis and the effect of albumin methods on albumin‐adjusted IMA levels. A total of 30 ESRD patients were included in this study. Serum IMA and albumin levels were measured before and after a hemodialysis session. Albumin concentrations were determined with bromocresol green and bromocresol purple methods. Postdialysis IMA and albumin‐adjusted IMA levels with two different albumin methods were significantly increased compared with the predialysis levels ( P <0.05). However, we did not find any difference in albumin‐adjusted IMA levels in either at the beginning or at the end of the dialysis session. IMA levels increase after hemodialysis, whereas albumin method has no effect on albumin‐adjusted IMA levels. J. Clin. Lab. Anal. 24:273–277, 2010. © 2010 Wiley‐Liss, Inc.